Posters

Influence of the IOL design on capsular bag stability in patients with pseudoexfoliation syndrome

Poster Details

First Author: M.Weber AUSTRIA

Co Author(s):    P. Draschl   N. Hirnschall   O. Findl              

Abstract Details

Purpose:

To evaluate the influence of two different intraocular lens (IOL-) designs on postoperative IOL stability concerning IOL tilt and decentration in patients with pseudoexfoliation syndrome (PES).

Setting:

Vienna Institute for Research in Ocular Surgery, A Karl Landsteiner Institute, Department of Ophthalmology, Hanusch Hospital, Vienna

Methods:

This randomised trial included patients diagnosed with PES who were scheduled for cataract surgery. Randomly in one eye of each patient the Tecnis 1-piece ZCB00 (AMO, USA) was implanted while in the other eye the Acrysof SA60AT (ALCON, USA) was implanted. Both IOLs are hydrophobic acrylic open loop IOLs. Main difference is that the anterior surface is concave to the optic edge in the Tecnis IOL which results in a missing central anterior capsule contact. Aim of this study was to assess differences in anterior chamber depth (ACD) and in IOL tilt and IOL decentration between test and control eyes.

Results:

Fourty eyes of 20 patients were included. Mean ACD in test and control eyes was 5.12±0.35mm and 4.80±0.24mm 1 hour post-operatively and 5.11±0.34mm and 4.64±0.35mm 1 year post-operatively (p<0.01 and p<0.01). Mean IOL decentration 1 hour post-operatively was 0.3±0.2mm in both eyes and 1 year post operatively 0.5±0.1mm in the test eye and 0.4±0.2mm in the control eye (p=0.53 and p=0.36). Mean IOL tilt in test and control eyes was 2.9±1.5° and 3.6±2.0° 1 hour post-operatively and 3.2±2.0° and 4.5±2.2° 1 year post-operatively (p=0.45 and p=0.18).

Conclusions:

In eyes with pseudoexfoliation syndrome where the Tecnis 1-piece ZCB00 was implanted the anterior chamber is slightly deeper 1 year post-operatively in comparison to eyes where the Acrysof SA60AT was implanted. No differences were found in tilt and decentration between these IOLs 1 year post-operatively.

Financial Disclosure:

NONE